MedTrace Logo

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

NCT02521649 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-08-13

No results posted yet for this study

Summary

An open, dose-ranging, multiple dose, multi-centre study in patients with Stage I-III or Stage IV gastric cancer. Twelve patients in each of 5 treatment groups were to receive three injections at weeks 0, 2 and 6 with provision for a single booster injection in an extension study period.

Conditions

Interventions

DRUG

G17DT

Sponsors & Collaborators

  • Clinical Project Services

    collaborator UNKNOWN

  • MPS Research Unit

    collaborator UNKNOWN

  • Cancer Advances Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Primary Completion
2001-01-31
Completion
2001-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02521649 on ClinicalTrials.gov